Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Darolutamide

Review the clinical trials studying darolutamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-19 of 19

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Status: Active
Location: 555 locations
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 258 locations
Testing the Anti-cancer Drug Darolutamide in Patients with Testosterone-Driven Salivary Gland Cancers
Status: Active
Location: 27 locations
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Status: Active
Location: 17 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Status: Active
Location: 7 locations
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Status: Active
Location: 5 locations
MRI-Guided LEAD Stereotactic Radiotherapy with or without Ultra-Short Term Androgen Suppression Therapy for the Treatment of Prostate Cancer, the Miami UAdapt Trial
Status: Active
Location: 4 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for the Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Status: Active
Location: 3 locations
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Status: Active
Location: 2 locations
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Status: Active
Location: 2 locations
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Adaptive Androgen Deprivation Therapy and Docetaxel for the Treatment of Metastatic Castration Sensitive Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Status: Active
Location: See ClinicalTrials.gov
Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer
Status: Active
Location: 2 locations
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Status: Active
Location: 2 locations